+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Nucleic Acid-Based Drugs Market by Drug Type, Molecule Type, Route of Administration, Therapeutic Area, End-User - Global Forecast to 2030- Product Image
Nucleic Acid-Based Drugs Market by Drug Type, Molecule Type, Route of Administration, Therapeutic Area, End-User - Global Forecast to 2030- Product Image
Sale

Nucleic Acid-Based Drugs Market by Drug Type, Molecule Type, Route of Administration, Therapeutic Area, End-User - Global Forecast to 2030

  • PDF Icon

    Report

  • 196 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6013698
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Nucleic Acid-Based Drugs Market is advancing swiftly, powered by breakthroughs in gene modulation and novel delivery platforms. Senior decision-makers operating within this sector face a complex landscape shaped by regulatory shifts, technology innovation, and evolving supply chain strategies. This report delivers actionable market clarity designed for executive insight and strategic planning.

Market Snapshot: Growth Trajectory for Nucleic Acid-Based Drugs

The global nucleic acid-based drugs market expanded from USD 33.37 billion in 2024 to USD 37.76 billion in 2025 and is forecast to achieve USD 70.95 billion by 2030, at a CAGR of 13.39%. Nucleic acid therapeutics—including antisense oligonucleotides, aptamers, mRNA constructs, nucleoside analogs, and RNA interference therapeutics—are gaining momentum across diverse disease indications. Robust clinical validation and the success of mRNA-based therapies signal a decisive transformation in the pharmaceutical landscape, drawing increased investments and public-private partnerships. Advanced manufacturing techniques and adaptive regulatory pathways further support accelerated market entry and portfolio diversification.

Scope & Segmentation: Market Coverage and Structure

This report provides comprehensive segmentation and analysis of the nucleic acid-based drugs industry, detailing technologies, therapeutic focus, and global regional opportunities. Key market dimensions include:

  • Drug Types: Antisense oligonucleotides, DNA/RNA aptamers, mRNA-based therapeutics, nucleoside analogs, RNA interference therapeutics (including miRNA, shRNA, siRNA)
  • Molecule Types: Large molecules, small molecules
  • Routes of Administration: Inhalation, intramuscular, intravenous, oral, subcutaneous
  • Therapeutic Areas: Cardiovascular diseases, infectious diseases (bacterial, fungal, viral), metabolic disorders, neurological disorders, oncology (hematologic, solid tumors), rare diseases
  • End-Users: Academic and research institutes, contract research organizations, hospitals and clinics, pharmaceutical and biotechnology companies
  • Regions Covered: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe/Middle East/Africa (including UK, Germany, France, UAE, Saudi Arabia, South Africa, and others), Asia-Pacific (including China, India, Japan, Australia, South Korea, Singapore, and additional APAC countries)
  • Key Players Analyzed: Companies such as Alnylam Pharmaceuticals, Amgen, Arcturus Therapeutics, Arrowhead Pharmaceuticals, AstraZeneca, and others are profiled for strategic benchmarking.

Technology and Regional Dynamics

  • Innovative Platforms: High-fidelity nucleotide synthesis, lipid nanoparticles, AI-driven sequence design, and CRISPR-based editing tools
  • Manufacturing Advances: Modular, flexible manufacturing for scale-up; integration of automated purification and bioprocessing
  • Global Differentiation: Americas lead with research infrastructure and venture capital; Europe excels in regulatory frameworks; Asia-Pacific expands contract manufacturing and local partnerships

Key Takeaways: Strategic Insights for Senior Leaders

  • Pipeline diversification is accelerating through collaborations between pharmaceutical leaders, biotechnology innovators, and academic centers.
  • Value creation is shifting toward targeted therapies addressing unmet needs in oncology, rare diseases, and infectious disease, underpinned by precision gene modulation.
  • Regulatory agencies are adopting adaptive approval pathways, supporting faster clinical translation of next-generation nucleic acid drugs.
  • Integration of artificial intelligence and automation optimizes candidate selection, helping reduce development timelines and operational bottlenecks.
  • Regional ecosystems—such as APAC’s manufacturing scale and North America’s data-driven R&D—are reshaping competition and strategic expansion.

Impact of 2025 US Tariff Adjustments

Forthcoming US tariffs will impact supply chain economics for nucleic acid-based drugs by increasing costs for specialized raw materials. Companies are reassessing their sourcing strategies, exploring vertical integration and regional manufacturing partnerships to manage these pressures. Contract research organizations and academic partners may face constraints in early-phase and preclinical activities. Some industry players consider alternate manufacturing hubs and converting capital investments into long-term regional resilience. Industry coalitions continue to engage with policymakers for potential exemptions or relief on biopharmaceutical inputs.

Methodology & Data Sources

This research report integrates primary interviews with industry experts and secondary analysis of peer-reviewed literature, patent data, and regulatory filings. Data triangulation and thematic analysis ensure accurate, actionable insights grounded in robust evidence.

Why This Report Matters

  • Supports executive decision-making with deep segmentation, regional trend analysis, and competitive benchmarking tailored to strategic planners.
  • Enables rapid evaluation of new therapeutic and technology opportunities, supporting informed investment, partnership, and operational choices.
  • Mitigates market uncertainty by providing clarity on supply chain, regulatory, and competitive factors relevant to nucleic acid therapeutics.

Conclusion

Nucleic acid-based drugs are redefining therapeutic innovation and commercial strategy. Market leaders who align portfolios and operations with emerging technologies and shifting policies are well-positioned to capture new opportunities. This intelligence offers actionable guidance for sustained growth in a dynamic healthcare environment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Nucleic Acid-Based Drugs Market, by Drug Type
8.1. Introduction
8.2. Antisense Oligonucleotides
8.3. DNA/RNA Aptamers
8.4. mRNA-Based Therapeutics
8.5. Nucleoside Analogs
8.6. RNA Interference (RNAi) Therapeutics
8.6.1. MicroRNA (MiRNA)
8.6.2. Short Hairpin RNA (ShRNA)
8.6.3. Short Interfering RNA (SiRNA)
9. Nucleic Acid-Based Drugs Market, by Molecule Type
9.1. Introduction
9.2. Large Molecule
9.3. Small Molecule
10. Nucleic Acid-Based Drugs Market, by Route of Administration
10.1. Introduction
10.2. Inhalation
10.3. Intramuscular
10.4. Intravenous
10.5. Oral
10.6. Subcutaneous
11. Nucleic Acid-Based Drugs Market, by Therapeutic Area
11.1. Introduction
11.2. Cardiovascular Diseases
11.3. Infectious Diseases
11.3.1. Bacterial Infections
11.3.2. Fungal Infections
11.3.3. Viral Infections
11.4. Metabolic Disorders
11.5. Neurological Disorders
11.6. Oncology
11.6.1. Hematologic Malignancies
11.6.2. Solid Tumors
11.7. Rare Diseases
12. Nucleic Acid-Based Drugs Market, by End-User
12.1. Introduction
12.2. Academic & Research Institutes
12.3. Contract Research Organizations
12.4. Hospitals & Clinics
12.5. Pharmaceutical & Biotechnology Companies
13. Americas Nucleic Acid-Based Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Nucleic Acid-Based Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Nucleic Acid-Based Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Alnylam Pharmaceuticals, Inc.
16.3.2. Amgen Inc.
16.3.3. Arcturus Therapeutics Holdings Inc.
16.3.4. Arrowhead Pharmaceuticals, Inc.
16.3.5. AstraZeneca PLC
16.3.6. Beam Therapeutics Inc.
16.3.7. Biogen, Inc.
16.3.8. BioMarin Pharmaceutical Inc.
16.3.9. BioNTech SE
16.3.10. Bluebird Bio, Inc.
16.3.11. CRISPR Therapeutics AG
16.3.12. CureVac N.V.
16.3.13. Dynavax Technologies Corporation
16.3.14. Editas Medicine, Inc.
16.3.15. Eli Lilly and Company
16.3.16. Evotec SE
16.3.17. F. Hoffmann-La Roche Ltd.
16.3.18. Generation Bio Co.
16.3.19. Gilead Sciences, Inc.
16.3.20. GSK PLC
16.3.21. Intellia Therapeutics, Inc.
16.3.22. Ionis Pharmaceuticals, Inc.
16.3.23. Merck & Co., Inc.
16.3.24. Moderna, Inc.
16.3.25. Novartis AG
16.3.26. Novo Nordisk A/S
16.3.27. Orna Therapeutics, Inc.
16.3.28. Pfizer Inc.
16.3.29. ProQR Therapeutics N.V.
16.3.30. Sangamo Therapeutics, Inc.
16.3.31. Sanofi SA
16.3.32. Sarepta Therapeutics, Inc.
16.3.33. Silence Therapeutics PLC
16.3.34. Stoke Therapeutics, Inc.
16.3.35. Takeda Pharmaceutical Company Limited
16.3.36. Vertex Pharmaceuticals Incorporated
16.3.37. Voyager Therapeutics, Inc.
16.3.38. Wave Life Sciences Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. NUCLEIC ACID-BASED DRUGS MARKET MULTI-CURRENCY
FIGURE 2. NUCLEIC ACID-BASED DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. NUCLEIC ACID-BASED DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. NUCLEIC ACID-BASED DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. NUCLEIC ACID-BASED DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. NUCLEIC ACID-BASED DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DNA/RNA APTAMERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MRNA-BASED THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MICRORNA (MIRNA), BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT INTERFERING RNA (SIRNA), BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 62. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 63. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 64. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 65. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 66. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 67. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 68. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 69. CANADA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 70. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 71. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 72. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 73. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 75. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 76. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 77. MEXICO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 111. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 112. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 113. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 114. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 116. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 117. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 118. GERMANY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 119. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 120. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 121. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 122. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 124. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 125. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 126. FRANCE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 128. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 129. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 130. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 132. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 133. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 134. RUSSIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 135. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 136. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 137. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 138. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 140. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 141. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 142. ITALY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 143. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 144. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 145. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 146. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 148. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 149. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 150. SPAIN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 152. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 153. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 154. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 156. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 157. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 158. UNITED ARAB EMIRATES NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 164. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 165. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 166. SAUDI ARABIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 170. SOUTH AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 171. SOUTH AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 172. SOUTH AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 173. SOUTH AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 174. SOUTH AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 175. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 176. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 177. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 178. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 180. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 181. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 182. DENMARK NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 183. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 184. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 185. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 186. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 187. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 188. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 189. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 190. NETHERLANDS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 191. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 192. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 193. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 194. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 196. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 197. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 198. QATAR NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 199. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 200. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 201. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 202. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 204. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 205. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 206. FINLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 208. SWEDEN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 215. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 216. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 217. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 218. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 220. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 221. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 222. NIGERIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 223. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 224. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 225. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 226. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 227. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 228. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 229. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 230. EGYPT NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 231. TURKEY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 232. TURKEY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 233. TURKEY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 234. TURKEY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. TURKEY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 236. TURKEY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 237. TURKEY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 238. TURKEY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 240. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 241. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 242. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 243. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 244. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 245. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 246. ISRAEL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 247. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 248. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 249. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 250. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 251. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 252. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 253. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 254. NORWAY NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 255. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 256. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 257. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 258. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 259. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 260. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 261. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 262. POLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 266. SWITZERLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 267. SWITZERLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 268. SWITZERLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 269. SWITZERLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 270. SWITZERLAND NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 272. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 274. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 275. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 276. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 277. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 278. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 279. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 280. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 281. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 282. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 283. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 284. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 285. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 286. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 287. CHINA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 288. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 289. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 290. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 291. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 292. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 293. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 294. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 295. INDIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 296. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 297. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 298. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 299. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 300. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 301. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 302. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 303. JAPAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 304. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 305. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 306. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 307. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 308. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 309. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 310. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 311. AUSTRALIA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 312. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 313. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 314. SOUTH KOREA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 315. SOUT

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Nucleic Acid-Based Drugs market report include:
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Arcturus Therapeutics Holdings Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Beam Therapeutics Inc.
  • Biogen, Inc.
  • BioMarin Pharmaceutical Inc.
  • BioNTech SE
  • Bluebird Bio, Inc.
  • CRISPR Therapeutics AG
  • CureVac N.V.
  • Dynavax Technologies Corporation
  • Editas Medicine, Inc.
  • Eli Lilly and Company
  • Evotec SE
  • F. Hoffmann-La Roche Ltd.
  • Generation Bio Co.
  • Gilead Sciences, Inc.
  • GSK PLC
  • Intellia Therapeutics, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Orna Therapeutics, Inc.
  • Pfizer Inc.
  • ProQR Therapeutics N.V.
  • Sangamo Therapeutics, Inc.
  • Sanofi SA
  • Sarepta Therapeutics, Inc.
  • Silence Therapeutics PLC
  • Stoke Therapeutics, Inc.
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated
  • Voyager Therapeutics, Inc.
  • Wave Life Sciences Ltd.

Table Information

Report AttributeDetails
No. of Pages196
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 37.76 Billion
Forecasted Market Value ( USD ) by 2030 $ 70.95 Billion
Compound Annual Growth Rate13.3%
Regions CoveredGlobal
No. of Companies Mentioned39

Related Topics

Related Reports

Nucleic Acid Drug Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Nucleic Acid Drug Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Oligonucleotide Therapy Market Report 2025 - Product Image

Oligonucleotide Therapy Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Pharmaceutical Lipid-Based Excipients Global Market Report 2025 - Product Image

Pharmaceutical Lipid-Based Excipients Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Nanopharmaceuticals Market by Nanocarrier Type, Application, Route of Administration, End User - Global Forecast to 2030 - Product Image

Nanopharmaceuticals Market by Nanocarrier Type, Application, Route of Administration, End User - Global Forecast to 2030

  • Report
  • 185 Pages
  • Global
From
Specialty Drug Distribution Market by Distribution Channel, Therapeutic Area, Product Type, End User, Dosage Form - Global Forecast to 2030 - Product Image

Specialty Drug Distribution Market by Distribution Channel, Therapeutic Area, Product Type, End User, Dosage Form - Global Forecast to 2030

  • Report
  • 183 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.